These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 29708353)

  • 1. [Treatment of Metastatic Renal Cell Carcinoma].
    Richter I; Dvořák J
    Klin Onkol; 2018; 31(2):110-116. PubMed ID: 29708353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of current and future systemic therapy for metastatic renal cell carcinoma.
    Osawa T; Takeuchi A; Kojima T; Shinohara N; Eto M; Nishiyama H
    Jpn J Clin Oncol; 2019 May; 49(5):395-403. PubMed ID: 30722031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunotherapy of Renal Cell Carcinoma].
    Poprach A; Lakomý R; Büchler T
    Klin Onkol; 2017; 30(Supplementum3):55-61. PubMed ID: 29239194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery.
    Verzoni E; Ratta R; Grassi P; Salvioni R; Stagni S; Montone R; Fucà G; Cappelletti V; Reduzzi C; De Giorgi U; Procopio G
    Tumori; 2018 Oct; 104(5):401-405. PubMed ID: 29192741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
    J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology.
    Alhalabi O; Karam JA; Tannir NM
    Curr Opin Urol; 2019 Sep; 29(5):521-525. PubMed ID: 31305271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging therapeutics in refractory renal cell carcinoma.
    Koshkin VS; Rini BI
    Expert Opin Pharmacother; 2016 Jun; 17(9):1225-32. PubMed ID: 27112171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pilot Study on MicroRNAs as Biomarkers of Response to Sunitinib Treatment in Patients with Metastatic Renall Cell Carcinoma].
    Kováčová J; Juráček J; Poprach A; Büchler T; Kopecký J; Fiala O; Svoboda M; Lojová M; Slabý O
    Klin Onkol; 2018; 31(Supplementum1):161-162. PubMed ID: 29808694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.
    Patard JJ; Pignot G; Escudier B; Eisen T; Bex A; Sternberg C; Rini B; Roigas J; Choueiri T; Bukowski R; Motzer R; Kirkali Z; Mulders P; Bellmunt J
    Eur Urol; 2011 Oct; 60(4):684-90. PubMed ID: 21704448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combined Regimens in Immunotherapy].
    Melichar B; Spisarová M
    Klin Onkol; 2017; 30(Supplementum3):45-49. PubMed ID: 29239192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel.
    Halbert RJ; Figlin RA; Atkins MB; Bernal M; Hutson TE; Uzzo RG; Bukowski RM; Khan KD; Wood CG; Dubois RW
    Cancer; 2006 Nov; 107(10):2375-83. PubMed ID: 17048248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunotherapy for renal cell carcinoma - current status].
    Grimm MO; Foller S
    Aktuelle Urol; 2018 Apr; 49(2):187-191. PubMed ID: 29587324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
    Jain RK; Gandhi S; George S
    Urol Oncol; 2017 Nov; 35(11):640-646. PubMed ID: 28887097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is cytoreductive nephrectomy relevant in the immunotherapy era?
    Singla N; Ghandour RA; Margulis V
    Curr Opin Urol; 2019 Sep; 29(5):526-530. PubMed ID: 31305273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions.
    Donini M; Buti S; Massari F; Mollica V; Rizzo A; Montironi R; Bersanelli M; Santoni M
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):491-501. PubMed ID: 32479120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
    Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
    Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.
    Labriola MK; Batich KA; Zhu J; McNamara MA; Harrison MR; Armstrong AJ; George DJ; Zhang T
    Clin Genitourin Cancer; 2019 Jun; 17(3):e513-e521. PubMed ID: 30858035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidisciplinary systemic and local therapies for metastatic renal cell carcinoma: a narrative review.
    Zarba M; Fujiwara R; Yuasa T; Koga F; Heng DYC; Takemura K
    Expert Rev Anticancer Ther; 2024 Aug; 24(8):693-703. PubMed ID: 38813778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical decision-making for immunotherapy in metastatic renal cell carcinoma.
    Schmidinger M
    Curr Opin Urol; 2018 Jan; 28(1):29-34. PubMed ID: 29045250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic Body Radiotherapy - Current Indications.
    Burkoň P; Slavik M; Kazda T; Pospíšil P; Prochazka T; Vrzal M; Šlampa P
    Klin Onkol; 2019; 32(1):10-24. PubMed ID: 30894002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.